Semaglutide in CFRD

Part of paid clinical trials in Minneapolis, Minnesota.

Sponsor
University of Minnesota
Study ID
NCT05788965
Phase
PHASE2/PHASE3
Status
Completed

Conditions

  • Cystic Fibrosis
  • Cystic Fibrosis-related Diabetes

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    glucagon-like peptide 1 (GLP-1) receptor agonist

Study Details

This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).

Key Dates

Start date
Oct 16, 2023
Status verified
Jan 2026
Primary completion
Dec 23, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Single Arm
    Semaglutide 1 mg once weekly subcutaneous injection

Primary Outcome Measure

Weight [ Time Frame: 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of MinnesotaMinneapolisMinnesota55455-

Related coverage on Hipa.ai

Find similar trials in Minneapolis, MN

By research site
University of Minnesota· Minneapolis, MN

Related Studies